NCT00219271 2017-05-31
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Novartis
Phase 4 Completed
Clinical Trials
10 trialsNCT00237146 2017-02-23
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Novartis
Phase 4 Completed
NCT00242554 2017-02-23
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00334139 2017-02-07
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Novartis
Phase 4 Completed
NCT00172003 2016-11-18
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
Novartis
Phase 4 Completed
NCT00391690 2016-11-18
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Novartis
Phase 4 Completed
NCT00172016 2012-04-30
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Novartis
Phase 4 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00035997 2009-11-23
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Novartis
Phase 4 Completed